The researchers observed a significant and ...

New research has shown that the drug protects against damage to the bone side effects of certain medications. Published online early, reviewed scientific journal American Cancer Society, research has shown that some patients with breast cancer may take zoledronovoyi acid in addition to their anti-cancer drugs to maintain bone health. Drugs called aromatase inhibitors stop the production in postmenopausal women and thus make less estrogen available to stimulate the growth of some breast cancer cells. Many postmenopausal women with breast

regularly reviewed for several years with this potentially vital agents, but agents can lead to bone loss and fractures. Adam Brufsky, MD from the University of Pittsburgh Cancer Institute, and colleagues conducted a study to make sure that the bones acid zoledronovoyi drug can prevent and treat bone loss in postmenopausal patients with breast cancer. In his five-year study, called the Z-FAST, 602 postmenopausal women with early >> << receiving aromatase inhibitor Letrozole were randomized to receive zoledronovoyi acid simultaneously with Letrozole or only after the loss of bone mass and fractures occur lasix heart rate. The researchers observed a significant and progressive increase in bone density throughout the five-year study in women who initiated zoledronovoyi acid at the beginning, however, a significant reduction in bone density occurred when administration zoledronovoyi acid was postponed until bone loss was obvious. Over time, however, the rate of decline of bone density in the group delay slowed down, probably because more patients were delayed zoledronovoyi acid by the end of the study. These results show that bone density is stored more effectively in advance zoledronovoyi acid, but the loss of bone mass, most likely working, so start zoledronovoyi acid, even after the loss of bone mass is developed, is useful. This study shows that bone loss of aromatase inhibitors can be prevented long-term safe and effective drug that prevents osteoporosis, says Dr. Brufsky. Zoledronovoyi acid is currently approved in the U.S. Food and Drug Administration for conditions including osteoporosis and bone complications of cancer. Source:.